Treatment Outcomes Among Older Human Immunodeficiency Virus-Infected Adults in Nigeria

Open Forum Infectious Diseases
Patricia Aladi AgabaPhyllis J Kanki

Abstract

Older age at initiation of combination antiretroviral therapy (cART) has been associated with poorer clinical outcomes. Our objectives were to compare outcomes between older and younger patients in our clinical cohort in Jos, Nigeria. This retrospective cohort study evaluated patients enrolled on cART at the Jos University Teaching Hospital, Nigeria between 2004 and 2012. We compared baseline and treatment differences between older (≥50 years) and younger (15-49 years) patients. Kaplan-Meier analysis and Cox proportional hazard models estimated survival and loss to follow-up (LTFU) and determined factors associated with these outcomes at 24 months. Of 8352 patients, 643 (7.7%) were aged ≥50 years. The median change in CD4 count from baseline was 151 vs 132 (P= .0005) at 12 months and 185 vs 151 cells/mm3(P= .03) at 24 months for younger and older patients, respectively. A total of 68.9% vs 71.6% (P= .13) and 69.6% vs 74.8% (P= .005) of younger and older patients achieved viral suppression at 12 and 24 months, with similar incidence of mortality and LTFU. In adjusted hazard models, factors associated with increased risk of mortality were male sex, World Health Organization (WHO) stage III/IV, and having a gap in care, whereas be...Continue Reading

References

May 2, 2002·Journal of the American Geriatrics Society·Melissa Fair WellonsKenneth E Schmader
Sep 28, 2002·AIDS·Hernan ValdezUNKNOWN AIDS Clinical Trials Group Protocol 375 Team
Jan 11, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John L Perez, Richard D Moore
Nov 6, 2003·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Sheri WeiserRichard Marlink
Jan 2, 2004·European Journal of Public Health·Thomas Abel, Martin Werner
Apr 11, 2007·Archives of Internal Medicine·Michael J SilverbergCharles P Quesenberry
Apr 11, 2008·HIV Medicine·A MocroftUNKNOWN EuroSIDA study group
Aug 2, 2008·Bulletin of the World Health Organization·Martin W G BrinkhofUNKNOWN ART-LINC, IeDEA
Nov 6, 2008·Clinical Interventions in Aging·Nancy Nguyen, Mark Holodniy
Mar 14, 2009·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Jean B NachegaGary Maartens
Mar 3, 2012·AIDS·Eric BalestreUNKNOWN International epidemiological Database to Evaluate AIDS (IeDEA) West Africa Collaboration
Aug 17, 2012·AIDS Care·Benjamin H BaldersonSheryl Catz
Sep 14, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A Sarah WalkerUNKNOWN DART and ARROW trial teams
Dec 12, 2012·Current Opinion in Infectious Diseases·Fumiyo NakagawaAndrew Phillips
Oct 11, 2014·International Journal of Medical Informatics·Beth ChaplinPhyllis Kanki
Mar 4, 2015·Open Forum Infectious Diseases·Seema Thakore MeloniPhyllis Kanki
Jan 20, 2016·Journal of the International AIDS Society·Daniel O'BrienNathan Ford

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry

Software Mentioned

Epi
STATA

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.